Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*
Open Access
- 29 February 2012
- journal article
- Published by Elsevier BV
- Vol. 287 (6), 4198-4210
- https://doi.org/10.1074/jbc.m111.296475
Abstract
No abstract availableThis publication has 100 references indexed in Scilit:
- High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling*Published by Elsevier BV ,2011
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stressProceedings of the National Academy of Sciences of the United States of America, 2011
- The MMS22L-TONSL Complex Mediates Recovery from Replication Stress and Homologous RecombinationMolecular Cell, 2010
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical TargetsMolecular Cell, 2010
- PARP inhibition: PARP1 and beyondNature Reviews Cancer, 2010
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombinationThe EMBO Journal, 2009
- Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexesNucleic Acids Research, 2008
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- Role of poly(ADP-ribose) formation in DNA repairNature, 1992